|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM031560342 |
| 003 |
DE-627 |
| 005 |
20231221120601.0 |
| 007 |
tu |
| 008 |
231221s1988 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0106.xml
|
| 035 |
|
|
|a (DE-627)NLM031560342
|
| 035 |
|
|
|a (NLM)3174723
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Trabucchi, E
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Prevention of wound dehiscence in severely obese patients with jejuno-ileal by-pass
|b the role of hyaluronic acid
|
| 264 |
|
1 |
|c 1988
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.11.1988
|
| 500 |
|
|
|a Date Revised 17.11.2004
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a There is a high incidence of wound dehiscence, ranging from 6.9% to 22%, after surgery for severe obesity. Different surgical techniques to minimize this drawback of the operation have been proposed, but none have seemed to be really effective. A different approach to this problem has been tried using topical treatment with hyaluronic acid through the drains of the laparotomy suture. Twenty patients subjected to jejuno-ileal by-pass for severe obesity were randomized into two treatment groups: hyaluronic acid (80 mg/daily) or placebo (saline), for 5 days, starting at the operation. Granulation tissue was withdrawn from the wound through polyvinyl catheters 1, 3 and 5 days after the operation. It was processed for light, scanning and transmission electron microscopy. Ten days after the operation, the wounds were examined for dehiscence. Hyaluronic acid treatment reduced the incidence and degree of dehiscence macroscopically, increased the maturation of granulation tissue during the first post-operation days and stimulated fibroblasts to synthesize procollagen shortly after the operation
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Randomized Controlled Trial
|
| 650 |
|
7 |
|a Hyaluronic Acid
|2 NLM
|
| 650 |
|
7 |
|a 9004-61-9
|2 NLM
|
| 700 |
1 |
|
|a Foschi, D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Marazzi, M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Radaelli, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lucianetti, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rizzitelli, E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Baratti, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mariscotti, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Malgeri, C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Montorsi, W
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Interim guidelines for the control of infections with Vero cytotoxin producing Escherichia coli (VTEC). Subcommittee of the PHLS Working Group on Vero cytotoxin producing Escherichia coli (VTEC)
|d 1995
|g 5(1988), 4 vom: 11., Seite 233-9
|w (DE-627)NLM023961570
|
| 773 |
1 |
8 |
|g volume:5
|g year:1988
|g number:4
|g day:11
|g pages:233-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_39
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_121
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 5
|j 1988
|e 4
|b 11
|h 233-9
|